ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO903

Effects of Esculin Treatment on P2X7 Receptor and Klotho in Experimental Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic


  • Serralha, Robson Souza, Universidade Federal de São Paulo, Sao Paulo, Brazil
  • Rodrigues, Adelson, UNIFESP, Sao Paulo, Brazil
  • Rodrigues, Inri, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
  • Bertolini, Angela, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
  • Lima, Deyse, UNIFESP, Sao Paulo, Brazil
  • Nascimento, Moises, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
  • Mouro, Margaret G., UNIFESP, Sao Paulo, Brazil
  • Silva, Manoel, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
  • Punaro, Giovana, UNIFESP, Sao Paulo, Brazil
  • Higa, Elisa Mieko Suemitsu, Medicine Department/Unifesp, Sao Paulo, Brazil

Group or Team Name

  • Laboratory of Nitric Oxide and Oxidative Stress

P2X7 is a purinergic receptor which is activated under high concentrations of extracellular ATP, a common situation seen in diabetes mellitus, induced by the hyperglycemia. This receptor promotes calcium influx, which in large quantities activates biochemical processes culminating in programmed cell death. Constant activation of P2X7 induces inflammatory responses and oxidative stress. A previous study in our Laboratory showed a correlation between P2X7 and Klotho, since the latter can control phosphate metabolism. Coumarin derivates, as esculin, reduces oxidative damage seen in intestinal inflammation, arthritis and cognitive impairment related to diabetes. However, their pharmacodynamics are not yet fully understood. Thus, we aimed to evaluate the effects of esculin treatment on P2X7 receptor expression and Klotho in the kidneys of diabetic rats.


Male Wistar rats, 7 weeks old, received a single dose of streptozotocin (60 mg/kg; i.v.) for diabetes induction; control received only the drug vehicle. Diabetes was considered at blood glucose levels greater than 200 mg/dL. The animals received daily doses of esculin (50 mg/kg, p.o.), during 8 weeks, forming CTL+ESC and DM+ESC groups. 24-hours urine and a small aliquot of blood were collected for biochemical analysis and the rats were euthanized at the end of the protocol. The kidneys were collected for Western blotting. Statistical analysis was performed in GraphPad Prism 6 and the results are described as mean ± SEM; significance for p<0.05.


The diabetic rats presented 50% increase in P2X7 protein content when compared to CTL. DM group treated with ESC had a 46% decrease in P2X7; Klotho levels increased after ESC. We previously showed that Klotho, depleting phosphate, reduced P2X7 and protected the rats against diabetic nephropathy. Furthermore, DM treated with ESC also presented lower proteinuria (38.72±4.82 vs 45.42±3.0) and urinary TBARS (indicative of lipoperoxidation) (232.3±28.83 vs 282.0±7.2) when compared with untreated ones.


Our data suggest that decreased P2X7, perhaps via increasing Klotho, could be one of possible pathways for esculin to promote beneficial effects on the kidneys of diabetic animals.


  • Government Support - Non-U.S.